The company expects to see lower growth in products and services due to timing issues in obtaining billable cases from contracted customers.
The firm said the charges, related to deferred tax assets, revaluation of deferred tax liabilities, and other tax provisions, won't affect its adjusted EPS.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.
The firm's 14 percent growth in molecular diagnostics sales was driven primarily by continued strength across its Aptima women's health products globally.
GenMark placed 65 ePlex analyzers in Q3, the first full quarter after the platform's launch in the US, and it expects to exit 2017 with up to 200 placements.
The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.
The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.
Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.
The firm said that TB screening market growth was impacted by a slowdown in test utilization due to the White House's immigration policies.